Abstract

Vitamin C (ascorbic acid: AA) uptake in neurons occurs via the sodium-dependent vitamin C transporter-2 (SVCT2), which is highly expressed in the central nervous system (CNS). During chronic neuroinflammation or infection, CNS levels of lipopolysaccharide (LPS) and LPS-induced tumor necrosis factor-α (TNFα) are increased. Elevated levels of LPS and TNFα have been associated with neurodegenerative diseases together with reduced levels of AA. However, little is known about the impacts of LPS and TNFα on neuronal AA uptake. The objective of this study was to examine the effect of LPS and TNFα on SVCT2 expression and function using in vitro and in vivo approaches. Treatment of SH-SY5Y cells with either LPS or TNFα inhibited AA uptake. This reduced uptake was associated with a significant decrease in SVCT2 protein and mRNA levels. In vivo exposure to LPS or TNFα also decreased SVCT2 protein and mRNA levels in mouse brains. Both LPS and TNFα decreased SLC23A2 promoter activity. Further, the inhibitory effect of LPS on a minimal SLC23A2 promoter was attenuated when either the binding site for the transcription factor Sp1 was mutated or cells were treated with the NF-κB inhibitor, celastrol. We conclude that inflammatory signals suppress AA uptake by impairing SLC23A2 transcription through opposing regulation of Sp1 and NF-κB factors.

Highlights

  • Vitamin C is an essential micronutrient for cellular function, growth, and development, serving as a cofactor for an array of biological reactions and as a pleiotropic intracellular antioxidant [1, 2]

  • Plasma vitamin C levels are found to be significantly lower in patients with neurodegenerative diseases [3, 7,8,9,10]

  • Human tumor necrosis factor-α (TNFα) was bought from Invitrogen (Carlsbad, CA), and murine TNFα was from PeproTech, Inc. (Rocky Hill, NJ)

Read more

Summary

Introduction

Vitamin C (ascorbic acid: AA) is an essential micronutrient for cellular function, growth, and development, serving as a cofactor for an array of biological reactions and as a pleiotropic intracellular antioxidant [1, 2]. Accumulation of vitamin C in the brain cells occurs by a two-step mechanism, first by absorption across the choroid plexus and second by concentration into neurons and glia [4, 5]. The human sodium-dependent vitamin C transporter-2 (hSVCT2, the product of the SLC23A2 gene) controls these steps [4, 5]; knockout of murine SVCT2 results in undetectable levels of AA in the mouse brain [6]. Plasma vitamin C levels are found to be significantly lower in patients with neurodegenerative diseases [3, 7,8,9,10]. In Alzheimer’s disease (AD), reduced vitamin C levels may accelerate amyloid-beta (Aβ) accumulation and cognitive impairment [3, 7, 8, 11].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call